

Study of Oxidative Stress and One Carbon Metabolism in Prostate Neoplasm in a Tertiary Care Hospital

SOVAN SANNIGRAHI¹, DILIP KUMAR PAL², MOUSUMI MUKHOPADHYAY³

ABSTRACT

Introduction: Prostate neoplasm is a major health problem globally since last two decades. Among the contributory factors in aetiopathogenesis, oxidative stress and one carbon metabolism are also important.

Aim: To compare the serum level of vitamin B12, homocysteine and Malondialdehyde (MDA) between prostate cancer, Benign Prostatic Hyperplasia (BPH) and control subjects to find out the status of oxidative stress and one carbon metabolism in prostate tumours.

Materials and Methods: Forty patients each with BPH and Prostate cancer along with 40 age matched healthy controls were selected in an observational cross-sectional study, attending the outpatient and inpatient Department of Urology, IPGME&R, Kolkata, West Bengal, India, from January 2018 to June 2019. Oxidative stress for these patients was estimated by measuring lipid peroxidation product MDA by Thiobarbituric Acid Reactive Substances (TBARS) assay with spectrophotometer. Vitamin B12 and homocysteine were also analysed as a marker of one carbon metabolism by chemiluminescent method. Biochemical parameters such as fasting and post-prandial blood sugar,

urea, creatinine and liver function tests were measured by autoanalyser to rule out diabetes and any underlying hepatic and renal pathology. All the data were then analysed using statistical software SPSS version 24. The groups were compared using student's unpaired t-test and Pearson's correlation coefficient was applied to observe the correlation between variables.

Results: A statistically significant rise of oxidative stress was found in BPH and prostate cancer cases compared to age matched control. Regarding one carbon metabolism, this study fails to demonstrate any statistically significant difference of Vitamin B12 level between BPH and control as well as between prostate cancer and control group. However, high serum homocysteine is associated with both BPH and prostate cancer compared to the controls.

Conclusion: In the present study, statistically significant increase in oxidative stress and serum homocysteine level and no difference of serum vitamin B12 was found in BPH and prostate cancer cases compared to control group. Longitudinal studies are however required to establish any relationship and to investigate the potential role of homocysteine as a novel tumour marker.

Keywords: Homocysteine, Malondialdehyde, Reactive oxygen species, Vitamin B12

INTRODUCTION

Prostate cancer and BPH are the two most common forms of prostate tumour. Both are found predominantly in elderly males. Three quarter of the prostate cancer cases occur in men above 65 years of age with peak age of incidence between 70 and 74 years [1]. The disease is therefore more common in countries with higher proportions of elderly men in their population. Incidence of prostate cancer in India is lower than that in the Western populations. However, according to the National Health Profile 2019 [2], life expectancy in India has increased from 49.7 years in 1970-75 to 68.7 years in 2012-2016. This shift in the demographic picture has set the stage for an increased burden of diseases, specific to the elderly population. Incidence of prostate cancer as reported by Chatterjee A from a study in eastern India, revealed a drastic increase from 5.71% in 2003-2006 to 17.76% in 2007 and 28.97% in 2010 [3]. Most early stage prostate cancers are asymptomatic and difficult to detect clinically. The disease either becomes locally advanced or metastatic.

Aetiopathogenesis of prostate cancer includes, among various factors, oxidative stress and one carbon metabolism. The prooxidant-antioxidant balance of prostate cancer tissue is shifted towards a state of oxidative stress when compared to normal prostate tissue [4]. The existence of oxidative stress in prostate cancer is further supported by the beneficial role of various antioxidant trials [5]. Not only that, study had also shown that Reactive Oxygen Species (ROS) generation is essential for invasive phenotype of prostate cancer [6]. One carbon metabolism, on the other hand, has been linked to tumorigenesis through two principle pathways

of DNA methylation and DNA synthesis and repair. Methylation is a well-known epigenetic mechanism to silence gene expression. Methylation of CpG islands in the promoter region of genes may be especially pertinent in the prostate cancer development [7]. In addition, several other genes including tumour suppressors PTEN/MMAC1 and CDKN2, have been observed to be hyper methylated and inactivated in prostate cancer [7].

Keeping above background, parameters like MDA (for oxidative stress), Vitamin B12 and homocysteine (for status of the one carbon metabolism) were selected for the present study to investigate some of the multifactorial aetiology of prostate neoplasms. Study on these parameters in prostate neoplasms are very few in number and the results are also far from any definite conclusion. Hence, present study aims to compare serum level of these parameters between control, BPH and prostate cancer cases to find any association.

MATERIALS AND METHODS

Study Population

A cross-sectional observational study was conducted among patients either attending the outdoor or admitted in the in-patient Department of Urology and were scheduled for undergoing Trans-Rectal Ultrasound (TRUS) guided biopsy because of abnormally high Prostate Specific Antigen (PSA) value or Digital Rectal Examination (DRE) findings. The study was conducted during a time period of January 2018 to June 2019. Ethical clearance (IPGME&R/IEC/2018/313) was duly obtained from the Institutional Ethics Committee of Institute of Post-graduate Medical Education

and Research, Kolkata, West Bengal, India. Informed written consent was taken from each patient.

After exclusion of 40 patients based on exclusion criteria (female patients, histologically unconfirmed cases of BHP or prostate cancer, or the patients already receiving anti-cancer therapy or have already undergone surgical procedure for Ca prostate, patients with co-morbid conditions (eg. diabetes, obesity, dyslipidemia, hypertension, other cancers, liver diseases, renal failure), patients on anti-oxidants or multi-vitamin medications, or those who have altered PSA level for any other prostate pathology like prostatitis etc.), 80 subjects were selected as case for the study on the basis of predetermined inclusion and exclusion criteria in age group of 50-90 years and biopsy report of each case was collected from the pathology department. Out of these 80 cases, 40 patients had histopathologically confirmed BPH and 40 patients had histopathologically confirmed prostate cancer and they were labelled as two separate case group. Forty more subjects, who were apparently healthy and age matched, were chosen from the urology outpatient department as the control group.

Sampling Technique

A 5 mL of venous blood sample was drawn from a large peripheral vein of each subject in EDTA vial following strict aseptic precautions. Serum was separated by centrifugation (3500 rpm for 5 minutes) and stored at -20°C. All groups were assessed for MDA (by TBARS assay) and PSA, vitamin B12 and homocysteine (by chemiluminescent method). TBARS assay [8] is based on the acid catalysed decomposition of lipid hydroperoxides to MDA that reacts with Thiobarbituric Acid (TBA) to form a pink coloured chromogen, which is then evaluated spectrophotometrically at 532 nm. Vitamin B12, homocysteine (Hcy) and PSA were analysed by Chemiluminescent Immune Assay (CLIA) method (IMMULITE 1000 Homocysteine, Vitamin B12 and PSA kit, SIEMENS). Biochemical parameters such as fasting and post-prandial blood sugar, urea, creatinine and liver function tests were also measured (by spectrophotometric method) to rule out diabetes and any underlying hepatic and renal pathology which might have affected the study parameters if present.

STATISTICAL ANALYSIS

Data were analysed by software-Statistical Package for the Social Sciences (SPSS)-version 24. All variables are normally distributed by Kolmogorov-Smirnov goodness-of-fit test and the comparison between cases and controls were done by student's unpaired t-test. Analysis was two tailed and $p < 0.05$ was considered statistically significant.

Parameters	Control subjects (n=40) Mean±SD	BPH cases (n=40) Mean±SD	p-value*
Age (years)	67.83±7.296	69.55±7.649	0.305
PSA (ng/mL)	1.471±0.584	5.98±2.45	<0.0001
Hcy (μmol/L)	9.51±3.03	27.9±4.86	<0.0001
Vitamin B12 (ng/mL)	283.9±90.4	294.7±32.2	0.477
MDA (nmol/mL)	3.23±1.53	5.58±2.02	<0.0001
FBS (mg/dL)	93.93±7.43	95.9±4.21	0.637
PPBS (mg/dL)	131.55±5.8	130.46±2.45	0.452
Urea (mg/dL)	28.03±11.57	28.50±4.25	0.808
Creatinine (mg/dL)	0.95±0.123	0.914±0.127	0.207
Total bilirubin (mg/dL)	0.750±0.179	0.783±0.211	0.459
Albumin (g/dL)	4.19±0.219	5.12±1.24	0.598
SGPT (U/L)	30.43±3.01	31.2±0.705	0.246

[Table/Fig-1]: Comparing means of statistical data between control and BPH cases. *p-value calculated by student's unpaired t-test; PSA: Prostate specific antigen; Hcy: Homocysteine; MDA: Malondialdehyde; FBS: Fasting blood sugar; PPBS: Post prandial blood sugar; SGPT: Serum glutamic pyruvic transaminase

RESULTS


In the present study, 120 subjects (80 cases and 40 control) were included. Mean age of control, BPH and Prostate cancer cases was 67.83±7.3, 69.55±7.6 and 66.00±9.4 years, respectively [Table/Fig-1,2].

Parameters	Control subjects (n=40) Mean±SD	Prostate cancer (n=40) Mean±SD	p-value*
Age (years)	67.83±7.296	66.00±9.430	0.336
PSA (ng/mL)	1.471±0.584	42.9±10.7	<0.0001
Hcy (μmol/L)	9.51±3.03	54.2±11.9	<0.0001
Vitamin B12 (ng/mL)	283.9±90.4	314.4±68.7	0.094
MDA (nmol/mL)	3.23±1.53	35.8±9.45	<0.0001
FBS (mg/dL)	93.93±7.43	97.5±6.99	0.437
PPBS (mg/dL)	131.55±5.8	135.7±5.24	0.342
Urea (mg/dL)	28.03±11.57	27.7±5.52	0.871
Creatinine (mg/dL)	0.95±0.123	0.957±0.043	0.718
Total bilirubin (mg/dL)	0.750±0.179	0.755±0.179	0.559
Total protein	7.12±0.249	7.085±0.267	0.492
Albumin (g/dL)	4.19±0.219	4.44±0.678	0.669
SGPT (U/L)	30.43±3.01	33.2±3.12	0.14

[Table/Fig-2]: Comparing means of statistical data between control and prostate cancer cases.

*p-value calculated by student's unpaired t-test; PSA- Prostate specific antigen; Hcy: Homocysteine; MDA: Malondialdehyde; FBS: Fasting blood sugar; PPBS: Post prandial blood sugar; SGPT: Serum glutamic pyruvic transaminase


When means were compared (by student's unpaired t-test) between control and BPH cases, difference of MDA and Hcy was found statistically significant ($p < 0.0001$ for both MDA and Hcy), whereas no significant difference of vitamin B12 ($p = 0.477$) was found. Comparison of other parameters was not significant [Table/Fig-1]. Similarly, between control and prostate cancer group, there was statistically significant difference for MDA and Hcy ($p < 0.0001$) but difference for vitamin B12 was insignificant ($p = 0.094$). For rest of the parameters, comparison was statistically not significant [Table/Fig-2]. The above comparisons were also demonstrated in box plot [Table/Fig-3-5].




[Table/Fig-3]: Comparison of MDA between control, BPH and PC case.

Variables were compared between them in BPH and prostate cancer separately and Pearson's correlation coefficient was calculated. In BPH, correlation between PSA and MDA showed a positive correlation (correlation coefficient $r = 0.122$, p -value = 0.455). Similar positive correlation was also found in BPH between PSA and Hcy ($r = 0.368$, $p = 0.020$) and between PSA and Vitamin B12 ($r = 0.217$, p -value = 0.179) [Table/Fig-6]. On the other hand, in prostate cancer, a positive correlation was found between PSA and Vitamin B12


($r=0.063$, $p\text{-value}=0.697$), as well as between PSA and Hcy ($r=0.226$, $p=0.160$). However, correlation between PSA and MDA in Prostate cancer was negative ($r=-0.282$, $p\text{-value}=0.078$) [Table/Fig-7].



[Table/Fig-4]: Comparison of vitamin B12 Between control, BPH and PC case.




[Table/Fig-5]: Comparison of HCY between control, BPH and PC case.



[Table/Fig-6]: Scatter diagram showing correlation between MDA, Vitamin B12, Hcy and PSA in BPH.

DISCUSSION

Aetiology of prostate neoplasms is multifactorial. Epidemiological studies have implicated a range of possible aetiological factors (such as high saturated fat intake, low intake of carotenoids, vasectomy and other sexual factors, high serum androgen levels [4], family history of prostate cancer, and increased generation of ROS) responsible for the development of the above-mentioned diseases. In the present study some representative biochemical parameters among the causative agents had been studied in patients of prostate neoplasm and compared with the control group.



[Table/Fig-7]: Scatter diagram showing correlation between MDA, Vitamin B12, Hcy and PSA in prostate cancer.

The MDA level, measured as a marker of oxidative stress was found significantly increased in BPH and prostate cancer patients when compared to control group. Oxidative stress develops when there is excess of free radical generation and/or decreased activity of antioxidant system. In prostate cancer, both of these mechanisms may contribute to a state of oxidative stress. Increased generation of free radicals in prostate cancer may be due to dietary fat consumption, androgen exposure or inflammation in prostate tumour tissue. Whereas decreased antioxidant activity such as lowered intracellular glutathione reserve and decreased activity of some antioxidant enzyme systems (e.g., gamma glutamyl transpeptidase) may also be caused by androgen exposure [4]. According to one model of prostate carcinogenesis, chronic infection leads to chronic inflammation, and defects in antioxidant enzymes, DNA repair mechanisms, and apoptosis, which later combine to initiate carcinogenesis. Oxidative stress cause DNA damage in the form of strand breakage, base modifications, DNA protein cross linkages that in turn lead to further mutation, chromosomal aberration, genomic instability and eventually cancer. Activation of transcription factors (e.g., NF- κ B) by oxidative stress alter intracellular signal transduction system to induce proto-oncogenes such as c-fos, c-myc oncogenes and cause p 53 mutation [9] bringing about the progression of cancer. On the other hand, free radical mediated oxidative stress plays an important role in the pathogenesis of BPH. Studies have shown higher level of oxidative stress marker such as 8-OH deoxyguanosine (8-OH dG) [10] and decreased level of antioxidant enzymes such as Superoxide Dismutase (SOD), glutathione peroxidase in BPH. From the results of the present study, analysis for oxidative stress markers may be proposed and provision of antioxidant medicine supplementation along with the conventional treatment protocol might also be considered for these patients. One carbon determinant has been reported to be involved in cancer development, but results vary according to the tissue of origin of the malignancy [11].

In the present study, the members related to one carbon metabolism like vitamin B12, and homocysteine were measured. The enzyme methionine synthase requires Vit B12 as coenzyme and the reaction also involves recycling of tetrahydrofolate which may be utilised for nucleotide biosynthesis. That is why, cancer patients are expected to have low plasma folate because tumour cells, due to high rate of cell division utilise folate from circulation to synthesise DNA (de-novo purine synthesis). On the other hand, relatively high folate status is generally known to reduce risk of cancer development. This protective effect of folate level was documented in colon cancer [11]. However, based on the above fact, supplementation of folate has not been beneficial in cancer patients [12], rather it has accentuated advanced lesion in the folate supplemented groups when compared to placebo arm. Vitamin B12, a closely related compound to folate metabolism was measured in the BPH and prostate cancer patients. The level of serum vitamin B12 was 283.9 ± 90.4 in control subjects vs $(314.4 \pm 68.7, p > 0.05)$ in prostate cancer patients and $(294 \pm 32.2, p > 0.05)$ in BPH patients. Thus, the difference has no statistical

significance. These results were in accordance with a nested control study by Weinstein SJ et al., and Johansson M et al., which found no significant association for circulating Vitamin B12 with prostate cancer risk [13,14]. The unequivocal results may partially originate from the dual effect of folate in carcinogenesis. Epigenetic events affect gene expression without altering the actual sequence of DNA. Examples include DNA hypomethylation (may involve Vit B12), chromatin remodeling, histone modification, and RNA interference. Other than methylation, folate by promoting synthesis of thymidylate from uracil exerts its protective effect (may not be dependent on Vit B12). Mis-incorporation of uracil in DNA increases genomic instability and leads to cancer [15]. Another study by Collin SM et al., found positive association of increased serum vitamin B12 concentration with prostate cancer risk (highest versus lowest quartile of B12 Odds Ratio (OR)=1.17 (95% confidence interval, 0.95-1.43) [16]. Interestingly, hypermethylation of CpG island sequences of the Glutathione S-Transferase k gene (GSTP1) is a frequently reported epigenetic change in prostate cancer [7], which may require increased activity of Vitamin B12 as coenzyme. Thus, the results of studies on the associations of circulating vitamin B12 and risk of prostate cancer are highly varied and far from any definite conclusion yet.

In this study, Hcy was also measured in all three groups. Serum Hcy level was 2.93-folds higher in BPH cases and 5.69 folds higher in prostate cancer cases compared to control group. Association of increased Hcy levels have been seldom reported in scientific literature. Study by Hultdin J et al., found increasing plasma Hcy levels associated with a reduced risk of borderline significance (OR=0.67; 95% CI=0.431-0.94; P-trend=0.08) [17]. However, after adjustment for other 2 plasma variables, BMI and smoking, the association becomes statistically non-significant (adjusted OR of 0.91 (95% CI=0.51-1.58; P-trend=0.60). In ProtecT study, Hcy were not associated with increased prostate cancer risk [16] and a 2003 study of Weinstein SJ et al., reported no association with prostate cancer risk for circulating concentrations of Hcy [13]. Global DNA hypomethylation is a common finding in prostate cancer. This epigenetic change is carried out by the enzyme methyl transferase which utilises S-adenosyl methionine or SAM as methyl donor. The SAM-to-SAH ratio determines cellular methylation potential and in hyper homocysteinemic state, this ratio decreases leading to decreased methylation potential [18].

Limitation(s)

The sample size was too small to generalise conclusions of test on other populations and thus raises concerns about type 1 error for significant findings and type 2 error for our null associations. Second limitation was the observational, cross-sectional design used in present study could only assess association, but could not confirm causal relationship for which a prospective study is needed. Thirdly, alcohol consumption, as well as drugs and gastrointestinal disorders interfering with folate or vitamin B12 bioavailability or uptake, such as antacids or certain anticonvulsants and gastritis or celiac disease, was also not addressed in the present study. Fourthly, association of parameters in localised vs advanced stage prostate cancer was not considered, which might have revealed more insight into the pathogenesis of prostate cancer and role of one carbon metabolites in it.

CONCLUSION(S)

The present study suggests that high level of oxidative stress is associated with prostate cancer and BPH cases compared to age matched control group. Possible role of antioxidant medications in modulating outcome in these patients, however needs exploration by randomised trials. In addition, it was also found that there was an association of high Hcy level and tumours of prostate origin whereas with vitamin B12, no association was documented. Further, longitudinal studies are required to establish any causal relationship. Association of hyper homocysteinemia with BPH and prostate cancer, if proved by larger prospective studies, may indicate the emergence of Hcy as a novel tumour marker in conjunction with PSA.

REFERENCES

- [1] Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2001/, 2004.
- [2] Watts K. National Health Profile 2019: The main takeaways [Internet]. [place unknown]: Health Issues India; 2019 [updated 2019 Nov 1; cited 2019 Nov 25]. Available from: <https://www.healthissuesindia.com/2019/11/01/national-health-profile-2019-the-main-takeaways/>.
- [3] Chatterjee A. Risk of prostate cancer in Eastern India. *Int J Can Res*. 2012;8(2):63-68.
- [4] Ripple MO, Wilding G, Henry WF, Rago RP. Prooxidant-Antioxidant shift induced by androgen treatment of human prostate carcinoma cells. *JNCI: J Natl Cancer Inst*. 1997;89(1):40-48.
- [5] Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: Results and lessons learned from β -carotene and retinol efficacy trial. *Cancer Epidemiol Biomarkers Prev*. 2003;12(6):518-26.
- [6] Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. *Cancer Res*. 2008;68(6):1777-85.
- [7] Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. *N Engl J Med*. 2003;349(4):366-81.
- [8] Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. *Am J Obstet Gynecol*. 1979;135(3):372-76.
- [9] Hainaut P, Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. *Cancer Res*. 1993;53(19):4469-73.
- [10] Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, et al. Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxy guanosine in human hepatocarcinogenesis. *Dig Dis*. 2013;31(5-6):459-66.
- [11] Giovannucci E. Modifiable risk factors for colon cancer. *Gastroenterol Clin North Am*. 2002;31(4):925-43.
- [12] Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. *JAMA*. 2007;297(21):2351-59.
- [13] Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R, Pietinen P, Barrett MJ, Taylor PR, et al. Null association between prostate cancer and serum folate, vitamin B6, vitamin B12, and homocysteine. *Cancer Epidemiol Biomarkers Prev*. 2003;12(11 Pt 1):1271-72.
- [14] Johansson M, Appleby PN, Allen NE, Travis RC, Roddam AW, Egevad L, et al. Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: Results from the European prospective investigation into cancer and nutrition study. *Cancer Epidemiol Biomarkers Prev*. 2008;17(2):279-85.
- [15] Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. *Adv Cancer Res*. 1998;72:141-96.
- [16] Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: A case-control study, systematic review, and meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2010;19(6):1632-42.
- [17] Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: A prospective study. *Int J Cancer*. 2005;113(5):819-24.
- [18] Loscalzo J, Handy DE. Epigenetic modifications: Basic mechanisms and role in cardiovascular disease (2013 grover conference series). *Pulm Circ*. 2014;4(2):169-74.

PARTICULARS OF CONTRIBUTORS:

1. Postgraduate Trainee, Department of Biochemistry, I.P.G.M.E & R, Kolkata, West Bengal, India.
2. Professor and Head, Department of Urology, I.P.G.M.E & R, Kolkata, West Bengal, India.
3. Professor and Head, Department of Biochemistry, I.P.G.M.E & R, Kolkata, West Bengal, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Dilip Kumar Pal,
244, A.J.C Bose Road, Department of Urology, I.P.G.M.E & R,
Kolkata-700020, West Bengal, India.
E-mail: drdkpal@yahoo.co.in

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS: [Jain H et al.]

- Plagiarism X-checker: Sep 07, 2019
- Manual Googling: Jan 23, 2020
- iThenticate Software: Feb 12, 2020 (11%)

ETYMOLOGY: Author Origin

Date of Submission: **Sep 06, 2019**
Date of Peer Review: **Oct 24, 2019**
Date of Acceptance: **Jan 23, 2020**
Date of Publishing: **Mar 01, 2020**